Sunday, July 26, 2026

The Dragon Tree (Dracaena): How could a realistic virtual earth for genetics +, and think #GStreetView w #GTimeSlider & #GPegman becoming our #AvatarAgentEHR at the #GCellView #GMoleculeView & #GQubitView levels help with the following 3 ER-100 gene drug therapy developments, & even be a game changer ? AND How best could World University and School, building on MIT OCW in 7 languages, begin to develop this iterating realistic virtual earth further (https://www.toolify.ai/ai-news/revolutionizing-education-with-machine-learning-and-ai-2574306), and in a #GrowWithGoogleWUaS program, and with the #GoogleQuantumComputer at the University of California, Santa Barbara ... and in the shop at 670 Ridgecrest Road, Canyon 94516? And see the reply in the PSs



How could a realistic virtual earth for genetics +, and think #GStreetView w #GTimeSlider & #GPegman becoming our #AvatarAgentEHR at the #GCellView #GMoleculeView & #GQubitView levels help with the following 3 ER-100 gene drug therapy developments, & even be a game changer ?  AND  How best could World University and School, building on MIT OCW in 7 languages, begin to develop this iterating realistic virtual earth further (https://www.toolify.ai/ai-news/revolutionizing-education-with-machine-learning-and-ai-2574306), and in a #GrowWithGoogleWUaS program, and with the #GoogleQuantumComputer at the University of California, Santa Barbara ... and in the shop at 670 Ridgecrest Road, Canyon 94516?    And see the reply in the PSs  

George Church <gchurch@genetics.med.harvard.edu>, norvig@stanford.edu, Ed Smyth MD <esmythmd@gmail.com>, Sid Mazumdar <sid.mazumdar@gmail.com>, Janie MacLeod <jkbmacleod@icloud.com>, Byron Hann <byronhann1@gmail.com>, Barbara van Schewick <schewick@stanford.edu>, Henry Robb <robb-h@comcast.net>, Roland Vogl <rvogl@law.stanford.edu>, Rolene Walker <rolenewalker@gmail.com>, "Matchett, David" <dmatchett@gmail.com>, "David S. Kong" <dkong@mit.edu>, Erica Robb Thaler <erica.thaler@uphs.upenn.edu>, Marc Dupuis <marco.dupuis@gmail.com>, Shawn T Flaherty <pgh.shawn@yahoo.com>, "Koehler, Peter F" <koehler@pitt.edu>, "Hildebrand, Gabrielle" <gabrielle@elasticmedia.com>, Joichi Ito <Joiito@gmail.com>, Konrad Alt <kalt104@gmail.com>, Mark MacLeod <mark_k_macleod@yahoo.com>, Lydia Pintscher <lydia.pintscher@wikimedia.de>, "Scott Yoga Mac Flower MacLeod (YogaMacFlower)" <yogamacflower@gmail.com>, Nancy O'Sullivan <n.osullivan@cox.net>, Nick Thompson <npt134@gmail.com>, Urs Gasser <Ugasser@gmail.com>, William Kelly <william.kelly@anthro.ox.ac.uk>, Tammie Vawter <mrs_califmacleod@yahoo.com>, Tom Hess <yogitom@comcast.net>, Robin Appleberry <robinappleberry@yahoo.com>



Dear George (Church), Peter (Norvig), Konrad (Alt), All, 

Greetings! 

1 
 Just asked Gemini AI this question, and got the following incredible reply: 

How could a realistic virtual earth for genetics +, and think #GStreetView w #GTimeSlider & #GPegman becoming our #AvatarAgentEHR at the #GCellView #GMoleculeView & #GQubitView levels help with the following 3 ER-100 gene drug therapy developments, & even be a game changer ?

AND 
How best could World University and School, building on MIT OCW in 7 languages, begin to develop this iterating realistic virtual earth further (https://www.toolify.ai/ai-news/revolutionizing-education-with-machine-learning-and-ai-2574306), and in a #GrowWithGoogleWUaS program, and with the #GoogleQuantumComputer at the University of California, Santa Barbara ... and in the shop at 670 Ridgecrest Road, Canyon 94516?  

And see the reply in the PSs 


2
Also just Tweeted in these regards: 




3
And just asked Google AI Search further - 

In building out a realistic virtual earth (https://www.toolify.ai/ai-news/revolutionizing-education-with-machine-learning-and-ai-2574306) in a n-dimensional WUaS hospital multimedia room in the shop in canyon 94516, and think #GStreetView w #GTimeSlider & #GPegman becoming our #AvatarAgentEHR at the #GCellView #GMoleculeView & #GQubitView levels, and for World university and School Pharma research and drug development too, with World Univ and Sch in a #GrowWithGoogleWUaS program, and for STEM research, what are the first electronics to get ?


"Building a multi-scale, n-dimensional virtual earth for educational and research purposes requires high-end GPU workstations, immersive XR headsets, and high-resolution displays. Essential infrastructure includes robust local networking and precision tracking devices for real-time visualization, ranging from cellular to quantum levels."

https://share.google/aimode/mwY5sQ4N3g9QvlXQy


4 
Seeking to do a variety of other things (and see related blog posts) like scientifically proving aging reversal experimentation in a realistic virtual earth as well.


Best regards, 
Scott 


PS 


1. How a Realistic Virtual Earth Framework Accelerates ER-100 and Epigenetic Drug Developments

A multi-scale, hyper-realistic digital Earth architecture integrated with #GStreetView, #GTimeSlider, and #GPegman—zooming seamlessly from macro-geography down through #GCellView, #GMoleculeView, and #GQubitView—could fundamentally transform ER-100 and similar epigenetic reprogramming therapies into a unified #AvatarAgentEHR ecosystem.

Here is how it acts as a game changer across three core developmental pillars:

A. Multi-Scale Delivery and Spatial Pharmacokinetics Tracking (#GStreetView to #GCellView)

  • The Challenge: Delivering a gene therapy via an AAV vector (such as ER-100’s intravitreal injection) requires precision spatial distribution. Off-target viral tropism or uneven diffusion across retinal ganglion cells can limit efficacy or create safety risks.
  • The Virtual Earth Impact: By coupling patient-specific spatial imaging with #GStreetView navigation scaled down to the #GCellView, researchers and AI simulation agents can trace vector diffusion in real time. #GPegman acts as an interactive digital agent navigating the vitreous humor, visualizing viral capsid binding on cell membranes, and mapping intracellular uptake at single-cell resolution. This eliminates guesswork in dosing windows and spatial distribution gradients.

B. Longitudinal Epigenetic Reversal and Temporal Control (#GTimeSlider)

  • The Challenge: Partial reprogramming relies on precise temporal control. ER-100 uses an oral doxycycline-inducible system to switch the OSK (Oct4, Sox2, Klf4) transcription factors on and off. Over-expression risks losing cell identity (dedifferentiation into stem-like states), while under-expression fails to clear accumulated epigenetic noise.
  • The Virtual Earth Impact: Integrating #GTimeSlider allows clinicians to scrub back and forth through a digital twin’s biological timeline. Users can observe how weeks of doxycycline exposure alter DNA methylation clocks, histone modification patterns, and mitochondrial output. The #AvatarAgentEHR can scrub forward to model the long-term safety of the 8-week pulse protocol, predicting cellular resilience months or years post-injection.

C. Quantum-Level Molecular Docking and Switch Precision (#GMoleculeView & #GQubitView)

  • The Challenge: Fine-tuning the binding affinity of the doxycycline-controlled transactivator, avoiding promoter leakage, and optimizing the structural conformation of the OSK transcription complex requires deep thermodynamic modeling.
  • The Virtual Earth Impact: Plummeting down to #GMoleculeView and #GQubitView shifts drug optimization into quantum chemistry domains. At the qubit scale, molecular simulations can calculate electron densities, atomic bond energies, and quantum state transitions of the transcription factors interacting with target promoter sequences. This atomistic clarity allows engineers to design next-generation variants (beyond ER-100) with ultra-tight safety switches, zero leakage, and customized tissue-specific affinities.

2. Epigenetic Reprogramming Trials: Europe vs. FDA Landscape

  • Current Status: The vanguard of clinical-stage epigenetic reprogramming is anchored heavily in the United States, led by Life Biosciences' ER-100. Following FDA clearance of its Investigational New Drug (IND) application in January 2026, the first-in-human Phase 1 clinical trial (NCT07290244) actively evaluates ER-100 for open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION).
  • European Landscape: While foundational longevity and epigenetic research are heavily anchored across European academic institutions (such as labs in the UK, Germany, and Switzerland), most corporate sponsors pursuing formal clinical trials for in vivo partial reprogramming file concurrently or position their early-stage trials under FDA/EMA frameworks designed for breakthrough regenerative medicines. European regulatory pathways (via the EMA) are closely watching the safety, biodistribution, and irreversible genome-safety profiles of these initial ophthalmic trials before systemic (non-eye-isolated) trials expand internationally. Because the eye serves as an immunologically privileged, compartmentalized organ, both US and European regulators have viewed it as the safest proving ground for human cellular rejuvenation.

3. Mechanism of OSK Yamanaka Factors in Cellular Age Resetting

Discovered by Shinya Yamanaka, the factors Oct4, Sox2, and Klf4 (OSK)—omitting c-Myc to avoid oncogenic tumor formation—reprogram cellular age through the following precise sequence:

  1. Erasing Epigenetic Noise: As cells age, their DNA sequence remains largely unchanged, but the epigenome degrades. DNA hypermethylation silences protective genes, while histone modifications drift, causing cells to "forget" their specialized programming.
  2. Rewriting Chromatin Accessibility: When introduced via a gene therapy vector and activated (such as via doxycycline with ER-100), the OSK transcription factors bind to closed, heterochromatin regions of the genome. They act as pioneer factors, physically opening up tightly coiled DNA structures.
  3. Restoring Youthful Transcriptional Programs: By opening these chromatin zones, OSK reactivates youthful gene expression networks. Damaged metabolic pathways are cleared, protein homeostasis (proteostasis) is restored, and mitochondrial function is revitalized.
  4. The "Partial" Boundary: In full reprogramming (adding c-Myc or driving expression too long), cells regress all the way to pluripotent stem cells (iPSCs), wiping out their identity. Partial reprogramming stops the clock midway—reviving youthful cellular vigor, repair mechanics, and electrical conductivity (crucial for retinal ganglion cells) while locking in the cell's original functional identity.

4. How ER-100 Could Expand Into a Whole Family of Related Pharmaceuticals

If ER-100 proves safe and effective in human clinical trials, it will serve as the validation template for a massive paradigm shift in pharmacology—moving from treating symptoms to restoring tissue youth. This platform can branch into a diverse family of therapeutics:

  • Systemic Organ-Targeted Pipelines (e.g., Metabolic and Hepatic): Following ocular delivery, similar vector designs can be engineered with liver-tropism (such as pipeline iterations like ER-300 targeting steatosis and metabolic dysfunction). By swapping local delivery for targeted intravenous or tissue-specific capsids, systemic diseases of aging can be tackled organ by organ.
  • Modular Transcription Factor Cocktails: While OSK represents the baseline for neuro-ocular and general rejuvenation, future variations can swap or augment these factors with tissue-specific master regulators (e.g., adding myogenic factors for skeletal muscle sarcopenia, or cardiogenic factors for post-infarct myocardial rejuvenation).
  • Tunable Small-Molecule Switches: The doxycycline-inducible architecture can be replaced or refined with other clinically validated, tightly controlled small-molecule ligand switches. This allows doctors to prescribe precise "rejuvenation dosing cycles" (e.g., a short 2-week therapeutic pulse every year) much like an annual biological tune-up.
  • Combination Regenerative Regimens: Future pharmaceuticals could combine epigenetic reset therapies with senolytics (to clear already senescent zombie cells) or direct gene-editing payloads, creating a comprehensive toolkit where a single platform family cures chronic degenerative diseases across neurology, cardiology, and endocrinology.





PPS
Asked these questions initially - 


1 
Are there any epigenetic reprogramming drug therapies going through clinical trials in Europe like er-100 and the fda?



2 
How do OSK Yamanaka factors work to reset cellular age?



3 
How could ER-100, if proven safe, become a whole family of related pharmaceuticals?






*
1 
are there any epigenetic reprogramming drug therapies going through clinical trials in europe like er-100 and the fda?



Yes, Life Biosciences has advanced ER-100 into human testing as the first partial epigenetic reprogramming therapy. Other deep-tech longevity groups like Altos Labs and NewLimit are developing similar cellular rejuvenation platforms, though their specific pipeline candidates remain largely in preclinical stages rather than active clinical trials. [1, 2, 3]
ER-100 Clinical Trial Status
    • Regulatory Clearance: The U.S. FDA cleared the Investigational New Drug (IND) application for ER-100 in January 2026. [1]
    • Human Dosing: The first patient was officially dosed in a Phase 1 clinical trial on June 9, 2026. [1]
    • Indications: Targeting optic nerve disorders, specifically open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). [1]
    • Mechanism: Uses a viral vector to deliver three Yamanaka factors (OCT4, SOX2, and KLF4, or OSK) locally via eye injection to restore a younger cellular state. [1, 2]
Regulatory Landscape in Europe and the US
    • FDA (United States): Actively overseeing the first-in-human Phase 1 safety trial for ER-100.
    • EMA (Europe): While traditional oncology and rare-disease "epi-drugs" (like HDAC or DNMT inhibitors for cancer) are approved or trialed through the European Medicines Agency, novel partial cellular reprogramming/rejuvenation gene therapies like ER-100 have not yet publicly initiated clinical trial sites in Europe. [1, 2, 3, 4, 5]
If you'd like, I can provide details on:
  • How the OSK Yamanaka factors work to reset cellular age
  • Other companies working on epigenetic reprogramming pipelines




* 
2 
How do OSK Yamanaka factors work to reset cellular age?


OSK Yamanaka factors reset cellular age through partial reprogramming by using specific proteins—Oct4, Sox2, and Klf4 (excluding c-Myc)—to erase harmful epigenetic damage while allowing mature cells to keep their specialized jobs. [1, 2]
How the Process Works
    • Partial Activation: Scientists turn on the OSK genes for only a short time so the cell becomes biologically younger without turning into an unspecialized stem cell. [1, 2]
    • Cleaning the Epigenome: As cells get old, chemical tags called DNA methylation markers drift and disrupt normal gene reading; OSK resets these old patterns back to a youthful state. [1, 2, 3, 4]
    • Restoring Function: Rejuvenated cells recover youthful gene activity, better energy production in mitochondria, and healthier protein maintenance. [1, 2]
    • Avoiding Danger: Leaving out the fourth factor, c-Myc, prevents the cells from rapidly multiplying out of control or forming tumors. [1, 2, 3, 4]
If you'd like, we can explore:
  • The difference between full and partial reprogramming
  • Current experiments testing this technology on vision loss and tissue aging







* 
3 
How could ER-100, if proven safe, become a whole family of related pharmaceuticals?


If proven safe, ER-100—an epigenetic therapy using OSK factors (OCT4, SOX2, KLF4)—could expand into a broad family of pharmaceuticals by swapping delivery vectors, modifying target tissues, and adjusting genetic payloads. [1, 2]
Adapting Delivery and Target Tissues
    • Different local organs: Using targeted injections or local delivery to treat other localized degenerative conditions, such as early-stage muscle, brain, or metabolic/liver diseases. [1]
    • Systemic administration: Engineering new vectors or lipid nanoparticles that safely reach widespread tissues instead of just eye cells via intravitreal injection. [1, 2]
Tweaking the Genetic Code and Control Switches
    • Alternative factors: Testing different combinations or subsets of transcription factors beyond OSK to fine-tune cellular resetting for specific cell types. [1]
    • Adjustable safety switches: Changing the molecular "on/off" trigger—such as replacing the doxycycline antibiotic control mechanism with other chemical or light-activated switches. [1, 2]
If you would like, I can provide more details on:
  • The specific mechanisms of partial reprogramming
  • The current Phase 1 clinical trial design for ER-100






PPPS
Also re World University and School and in becoming a major research university further, here's a recent blog post re WUaS research, and potentially developing a realistic virtual earth for most MIT OCW's 2500 courses, and also re grading research papers where students use AI: 






Society, Information Technology, and the Global University, (forthcoming, Academic Press at World University and School, 2026) 

Scottish Small Piping album #2 - Honey Piobaireachd (2022)
- Poetry! Order Book #5 Light, Float, Sit, Watsu ~ Virtually (2021, Academic Press at WUaS)

Scottish Small Piping album #1 Honey in the Bag ~ Out of the Air tune (2020)


Order Book #3 Winding Road Rainbow: Harbin, Wandering & the Poetry of Loving Bliss (2018,  Academic Press at WUaS)

Order Book #2 Haiku-ish and Other Loving Hippie Harbin Poetry (2017,  Academic Press at WUaS) 

Order Actual-Virtual Ethnographic Book #1: Naked Harbin Ethnography (2016, Academic Press at World University and School)


https://wiki.worlduniversityandschool.org/wiki/Nation_States (planning ~200 countries' WUaS world class universities in their main languages, per the Olympics, for free-to-students' WUaS degrees from home)

https://wiki.worlduniversityandschool.org/wiki/Languages (planning to be in all 7159 living languages, each as or with wiki schools for open people-to-people wiki-teaching and wiki-learning, e.g. from here - https://wiki.worlduniversityandschool.org/wiki/Subjects)

- Scott GK MacLeod  
Founder, President, CEO & Professor
at / of best STEAM CC licensed OCW, Wiki,
World University & School (WUaS)  
- USPS US Post Office, PO Box 132, General Delivery, Canyon, CA 94516

1) non-profit 501(c)(3) Public Charity
building on CC-4 licensed MIT OCW in 7 languages - 


2) for profit general stock company WUaS Corporation in CA - http://worlduniversityandschool.org/AcademicPress.html
- wuas_ceo@worlduniversityandschool.org
















* 






















https://en.wikipedia.org/wiki/Dracaena_(plant)

https://commons.wikimedia.org/wiki/Dracaena

https://commons.wikimedia.org/wiki/Category:Dracaena_draco

https://commons.wikimedia.org/wiki/Category:Dracaena

....



Posted by at
Labels: , , , , , , , , , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)